Jairo Mauricio Montezuma-Rusca
Research Subjects
Research Interests
Jairo Mauricio Montezuma-Rusca has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Amit Luthra
Affiliation Department of Medicine, UConn Health, Farmington, United States of America
1 shared publication- Carson J. La Vake
Affiliation Department of Pediatrics, UConn Health, Farmington, United States of America
1 shared publication - Charanpreet Padam
Division of Multiple Sclerosis and Translational Neuroimmunology, Department of Neurology, University of Connecticut School of Medicine, Farmington, CT 06030, United States
1 shared publication Christian Callebaut
Gilead Sciences, Inc
1 shared publication- Hamza Coban
Department of Neurology, University of Connecticut School of Medicine, University of Connecticut Health Center, Farmington, CT, USA
1 shared publication - Jaime Imitola
UConn Comprehensive Multiple Sclerosis and Neuroimmunology Center, Division of Neuroimmunology, Laboratory of Neural Stem Cells and Functional Neurogenetics, UConn Health, Farmington, CT 06030, USA; Department of Neurology, UConn Health, Farmington, CT 06030, USA
1 shared publication
Latest Publications
- Open Access
- 21 August 2026
- Published by SAGE Publications in Antiviral Therapy
- Vol. 31 (4)
Week 96 resistance analysis in participants receiving bictegravir/lenacapavir in the phase 2 ARTISTRY-1 study
Background: ARTISTRY-1 is an ongoing Phase 2/3 study evaluating the safety and efficacy of once-daily oral bictegravir (BIC) + lenacapavir (LEN) in virologically suppressed (VS; HIV-1 RNA <50 copies/mL) participants on complex antiretroviral (ARV) regimens. Here, we report Week 96 extension-phase data after transition to BIC/LEN single-tablet regimen (STR). Methods: Participants without known integrase strand-transfer inhibitor (INSTI) resistance were randomized (2:2:1) to BIC + LEN (75mg + 25mg or 75mg + 50mg) or stable background regimen, respectively. At the end of randomized treatment (mean of 69 weeks from baseline), participants could choose to enter the extension period and receive BIC/LEN 75/50 mg STR. Baseline resistance-associated mutations (RAMs) were evaluated from cumulative historical genotypic reports (HGRs) and Day 1 proviral DNA genotyping using a composite baseline sequence. Resistance testing was performed for confirmed virologic rebound. Results: Of 128 randomized/dosed participants, 119 entered the extension period and received BIC/LEN STR for a median time of 96 weeks (range 11–109) from end of randomization to cutoff date. Baseline RAMs were common (nucleoside reverse transcriptase inhibitor 82%, non-nucleoside reverse transcriptase inhibitor 66%, protease inhibitor 47%; INSTI RAMs 9% (proviral DNA)). Two participants met criteria for resistance testing before resuppressing, with no treatment-emergent capsid or integrase RAMs. All 119 participants were suppressed at last observed visit. Conclusions: Durable viral suppression was maintained for up to 96 weeks in the Phase 2 extension, with all participants in the extension phase maintaining virologic suppression and no treatment-emergent resistance to study drugs, supporting long-term virologic durability of BIC/LEN STR in VS individuals on complex ART.
- 21 August 2026
- Published by SAGE Publications in Antiviral Therapy
- Vol. 31 (4)
Open AccessWeek 96 resistance analysis in participants receiving bictegravir/lenacapavir in the phase 2 ARTISTRY-1 study
Background: ARTISTRY-1 is an ongoing Phase 2/3 study evaluating the safety and efficacy of once-daily oral bictegravir (BIC) + lenacapavir (LEN) in virologically suppressed (VS; HIV-1 RNA <50 copies/mL) participants on complex antiretroviral (ARV) regimens. Here, we report Week 96 extension-phase data after transition to BIC/LEN single-tablet regimen (STR). Methods: Participants without known integrase strand-transfer inhibitor (INSTI) resistance were randomized (2:2:1) to BIC + LEN (75mg + 25mg or 75mg + 50mg) or stable background regimen, respectively. At the end of randomized treatment (mean of 69 weeks from baseline), participants could choose to enter the extension period and receive BIC/LEN 75/50 mg STR. Baseline resistance-associated mutations (RAMs) were evaluated from cumulative historical genotypic reports (HGRs) and Day 1 proviral DNA genotyping using a composite baseline sequence. Resistance testing was performed for confirmed virologic rebound. Results: Of 128 randomized/dosed participants, 119 entered the extension period and received BIC/LEN STR for a median time of 96 weeks (range 11–109) from end of randomization to cutoff date. Baseline RAMs were common (nucleoside reverse transcriptase inhibitor 82%, non-nucleoside reverse transcriptase inhibitor 66%, protease inhibitor 47%; INSTI RAMs 9% (proviral DNA)). Two participants met criteria for resistance testing before resuppressing, with no treatment-emergent capsid or integrase RAMs. All 119 participants were suppressed at last observed visit. Conclusions: Durable viral suppression was maintained for up to 96 weeks in the Phase 2 extension, with all participants in the extension phase maintaining virologic suppression and no treatment-emergent resistance to study drugs, supporting long-term virologic durability of BIC/LEN STR in VS individuals on complex ART.
- 1 February 2021
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 48, 102731
Babesia microti infection in a patient with multiple sclerosis treated with ocrelizumab
- 1 February 2021
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 48, 102731
Babesia microti infection in a patient with multiple sclerosis treated with ocrelizumab
- Open Access
- 16 September 2020
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 16 (9) , e1008871
Evidence that immunization with TP0751, a bipartite Treponema pallidum lipoprotein with an intrinsically disordered region and lipocalin fold, fails to protect in the rabbit model of experimental syphilis
Deconvolution of syphilis pathogenesis and selection of candidate syphilis vaccinogens requires detailed knowledge of the molecular architecture of the Treponema pallidum outer membrane (OM). The T. pallidum OM contains a low density of integral OM proteins, while the spirochete’s many lipoprotein immunogens are periplasmic. TP0751, a lipoprotein with a lipocalin fold, is reportedly a surface-exposed protease/adhesin and protective antigen. The rapid expansion of calycin/lipocalin structures in the RCSB PDB database prompted a comprehensive reassessment of TP0751. Small angle X-ray scattering analysis of full-length protein revealed a bipartite topology consisting of an N-terminal, intrinsically disordered region (IDR) and the previously characterized C-terminal lipocalin domain. A DALI server query using the lipocalin domain yielded 97 hits, 52 belonging to the calycin superfamily, including 15 bacterial lipocalins, but no Gram-negative surface proteins. Surprisingly, Tpp17 (TP0435) was identified as a structural ortholog of TP0751. In silico docking predicted that TP0751 can bind diverse ligands along the rim of its eight-stranded β-barrel; high affinity binding of one predicted ligand, heme, to the lipocalin domain was demonstrated. qRT-PCR and immunoblotting revealed very low expression of TP0751 compared to other T. pallidum lipoproteins. Immunoblot analysis of immune rabbit serum failed to detect TP0751 antibodies, while only one of five patients with secondary syphilis mounted a discernible TP0751-specific antibody response. In opsonophagocytosis assays, neither TP0751 nor Tpp17 antibodies promoted uptake of T. pallidum by rabbit peritoneal macrophages. Rabbits immunized with intact, full-length TP0751 showed no protection against local or disseminated infection following intradermal challenge with T. pallidum. Our data argue that, like other lipoprotein lipocalins in dual-membrane bacteria, TP0751 is periplasmic and binds small molecules, and we propose that its IDR facilitates ligand binding by and offloading from the lipocalin domain. The inability of TP0751 to elicit opsonic or protective antibodies is consistent with a subsurface location. Development of a syphilis vaccine requires knowledge of the molecular architecture of the Treponema pallidum outer membrane (OM). The T. pallidum OM contains a paucity of integral OM proteins, while the spirochete’s lipoprotein immunogens are periplasmic. TP0751, a lipoprotein with a lipocalin fold, is reportedly a surface-exposed adhesin/protease and protective antigen. The recent increase in calycin/lipocalin structures prompted a comprehensive re-examination of TP0751. TP0751 contains two domains—an N-terminal intrinsically disordered region (IDR) and the previously characterized C-terminal lipocalin. Query of the structural databases identified related bacterial lipocalins, none known surface molecules. In silico docking studies predicted that TP0751 binds diverse ligands along the rim of its eight-stranded β-barrel and this was confirmed in heme binding assays. TP0751 is poorly expressed compared to other T. pallidum lipoproteins and barely elicits antibodies in syphilis immune rabbits or patients with secondary syphilis. TP0751 antibodies did not promote uptake of spirochetes by rabbit peritoneal macrophages, and immunization of rabbits with intact, full-length TP0751 did not prevent local or disseminated infection. Our data indicate that TP0751 resides within the periplasmic space of T. pallidum where it binds small molecules; we propose that the IDR facilitates ligand binding by and offloading from the lipocalin domain.
- 16 September 2020
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 16 (9) , e1008871
Open AccessEvidence that immunization with TP0751, a bipartite Treponema pallidum lipoprotein with an intrinsically disordered region and lipocalin fold, fails to protect in the rabbit model of experimental syphilis
Deconvolution of syphilis pathogenesis and selection of candidate syphilis vaccinogens requires detailed knowledge of the molecular architecture of the Treponema pallidum outer membrane (OM). The T. pallidum OM contains a low density of integral OM proteins, while the spirochete’s many lipoprotein immunogens are periplasmic. TP0751, a lipoprotein with a lipocalin fold, is reportedly a surface-exposed protease/adhesin and protective antigen. The rapid expansion of calycin/lipocalin structures in the RCSB PDB database prompted a comprehensive reassessment of TP0751. Small angle X-ray scattering analysis of full-length protein revealed a bipartite topology consisting of an N-terminal, intrinsically disordered region (IDR) and the previously characterized C-terminal lipocalin domain. A DALI server query using the lipocalin domain yielded 97 hits, 52 belonging to the calycin superfamily, including 15 bacterial lipocalins, but no Gram-negative surface proteins. Surprisingly, Tpp17 (TP0435) was identified as a structural ortholog of TP0751. In silico docking predicted that TP0751 can bind diverse ligands along the rim of its eight-stranded β-barrel; high affinity binding of one predicted ligand, heme, to the lipocalin domain was demonstrated. qRT-PCR and immunoblotting revealed very low expression of TP0751 compared to other T. pallidum lipoproteins. Immunoblot analysis of immune rabbit serum failed to detect TP0751 antibodies, while only one of five patients with secondary syphilis mounted a discernible TP0751-specific antibody response. In opsonophagocytosis assays, neither TP0751 nor Tpp17 antibodies promoted uptake of T. pallidum by rabbit peritoneal macrophages. Rabbits immunized with intact, full-length TP0751 showed no protection against local or disseminated infection following intradermal challenge with T. pallidum. Our data argue that, like other lipoprotein lipocalins in dual-membrane bacteria, TP0751 is periplasmic and binds small molecules, and we propose that its IDR facilitates ligand binding by and offloading from the lipocalin domain. The inability of TP0751 to elicit opsonic or protective antibodies is consistent with a subsurface location. Development of a syphilis vaccine requires knowledge of the molecular architecture of the Treponema pallidum outer membrane (OM). The T. pallidum OM contains a paucity of integral OM proteins, while the spirochete’s lipoprotein immunogens are periplasmic. TP0751, a lipoprotein with a lipocalin fold, is reportedly a surface-exposed adhesin/protease and protective antigen. The recent increase in calycin/lipocalin structures prompted a comprehensive re-examination of TP0751. TP0751 contains two domains—an N-terminal intrinsically disordered region (IDR) and the previously characterized C-terminal lipocalin. Query of the structural databases identified related bacterial lipocalins, none known surface molecules. In silico docking studies predicted that TP0751 binds diverse ligands along the rim of its eight-stranded β-barrel and this was confirmed in heme binding assays. TP0751 is poorly expressed compared to other T. pallidum lipoproteins and barely elicits antibodies in syphilis immune rabbits or patients with secondary syphilis. TP0751 antibodies did not promote uptake of spirochetes by rabbit peritoneal macrophages, and immunization of rabbits with intact, full-length TP0751 did not prevent local or disseminated infection. Our data indicate that TP0751 resides within the periplasmic space of T. pallidum where it binds small molecules; we propose that the IDR facilitates ligand binding by and offloading from the lipocalin domain.